President Donald Trump has selected Heidi Overton, a White House policy adviser and physician, to lead the Food and Drug Administration. The announcement came from Health and Human Services Secretary Robert F. Kennedy Jr. on X, first reported by Bloomberg News on Tuesday.
It would fill a vacancy that opened in May when former FDA commissioner Marty Makary stepped down. Kyle Diamantas, the agency’s deputy commissioner for food, has been acting in the role since then.
Overton’s background and the FDA’s challenges
Overton, a general surgery resident at Johns Hopkins University, joined the Trump administration in 2019 as a White House fellow. After the 2020 election, she moved to the America First Policy Institute, serving as chief policy officer and directing its Center for a Healthy America.
If confirmed, she would take charge of an agency that has seen significant turmoil. The FDA has dealt with mass layoffs, resignations of key officials, and criticism for inconsistent decisions under Makary’s leadership. Industry leaders and investors have raised concerns about the agency’s unpredictability, though Diamantas has brought some stability in recent months.
Related: User access denied after restriction
RBC Capital Markets analyst Brian Abrahams wrote in a note to clients that Overton’s influence on biopharma and drug reviews is uncertain. Her lack of direct regulatory experience in the pharmaceutical sector might mean she depends heavily on guidance from the White House and Kennedy.
Kennedy has praised Overton’s work in advancing his Make America Healthy Again agenda. The Atlantic reported that some of his followers believe she has slowed down his efforts during her work as deputy director of the White House Domestic Policy Council. White House officials told the magazine that she works carefully to make sure policies are advanced the right way.
A career shift from surgery to policy
Overton grew up as the daughter of a minister and an OB-GYN. She initially planned to become an oncology surgeon after graduating from the University of New Mexico’s medical school in 2015. Instead, she turned to policy, joining the White House after her residency.
At the America First Policy Institute, she took a strong stance against abortion and wrote about issues like opioid addiction and hospital price transparency. In a 2023 op-ed with former Louisiana Governor Bobby Jindal, she criticized Minnesota Governor Tim Walz, calling his policies extreme.
Related: Internet users report widespread access blocks
Her academic background includes a Ph.D. in clinical investigation from Johns Hopkins and board certification in public health and general preventive medicine. The FDA, based in White Oak, Maryland, regulates food safety, pharmaceuticals, and medical devices—areas that could change under her leadership if confirmed.
Overton’s appointment comes as the agency works to rebuild trust after a difficult period. Her ability to balance policy, politics, and public health will shape whether she can meet industry expectations.
For now, the FDA remains in transition. Diamantas continues to lead while the Senate considers Overton’s confirmation, a process that could take months.
